0001839882-24-021193.txt : 20240708 0001839882-24-021193.hdr.sgml : 20240708 20240708080524 ACCESSION NUMBER: 0001839882-24-021193 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240708 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240708 DATE AS OF CHANGE: 20240708 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 241103389 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp-8k_070824.htm CURRENT REPORT Current Report
false 0001430306 0001430306 2024-07-08 2024-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): July 8, 2024

 

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

26 Main Street, Chatham, New Jersey 07928

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

  Item 7.01 Regulation FD Disclosure.

 

On July 8, 2024, the Company announced receipt of the formal minutes from a recent pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) for its Tonmya™ product candidate for the management of fibromyalgia, and the completion of the second and final pre-NDA meeting. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01.Other Events.

 

On July 8, 2024, the Company announced receipt of the formal minutes from a recent pre-NDA meeting with the FDA for Tonmya™ for the management of fibromyalgia. At the meeting, the Company and the FDA agreed that proposed data package is sufficient to support the NDA submission for Tonmya. The Company reaffirmed its guidance to submit the NDA for Tonmya to the FDA in the second half of 2024.

  

Forward- Looking Statements 

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. 

 

  Item 9.01 Financial Statements and Exhibits.

 

(d)  

Exhibit

No.

   Description.
   

99.01

  

Press release of the Company, dated July 8, 2024

    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: July 8, 2024 By: /s/ Bradley Saenger  
    Bradley Saenger
    Chief Financial Officer

 
 EX-99.01 2 ex99-01.htm PRESS RELEASE

 

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

 

Exhibit 99.01

 

Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia

Approximately 10 million adults in the U.S. are affected by fibromyalgia, predominantly women

NDA submission target confirmed for second half 2024, with potential for FDA approval in second half 2025

CHATHAM, N.J., July 8, 2024 (GLOBE NEWSWIRE) – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced receipt of the formal minutes from a recent pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia. At the meeting, the Company and the FDA agreed that the proposed data package is sufficient to support the NDA submission. The Company reaffirmed its guidance to submit the NDA for Tonmya to the FDA in the second half of 2024 which would allow for a potential FDA approval in the second half of 2025.

“We are delighted with the results of this critical milestone meeting with the FDA to discuss our NDA, and we are appreciative of the FDA’s guidance throughout this process. We believe Tonmya has the potential to greatly benefit fibromyalgia patients, many of whom remain dissatisfied with the current treatment options, and many of whom turn to addictive, detrimental opioids as off-label treatments,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “The positive results from this pre-NDA meeting underscore the completeness of our data package in support of registration of Tonmya for the management of fibromyalgia.”

On June 20, 2024, Tonix announced receipt of formal minutes of a pre-NDA Type-B Chemistry, Manufacturing, and Controls (CMC) meeting confirming alignment with the FDA on key CMC topics to support the NDA submission. Today’s announcement confirms alignment with the nonclinical, clinical pharmacology and clinical features of the NDA submission, following completion of Tonix’s second and final pre-NDA meeting.

About Fibromyalgia

Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 6 million to 12 million adults in the U.S., the majority of whom are women. Symptoms of fibromyalgia include chronic widespread pain, non-restorative sleep, fatigue, and brain fog (or cognitive dysfunction). Other associated symptoms include mood disturbances, including anxiety and depression, headaches, and abdominal pain or cramps. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products. According to the recent report from the U.S. National Academies of Sciences, fibromyalgia is a diagnosable condition that may also occur in the context of Long COVID.1

 

 

 

 

 

 

About Tonmya* (also known as TNX-102 SL)

Tonmya is a centrally acting, non-opioid, non-addictive, bedtime investigational drug. The tablet is a patented sublingual formulation of cyclobenzaprine hydrochloride developed for the management of fibromyalgia. In December 2023, the company announced highly statistically significant and clinically meaningful topline results in RESILIENT, the second pivotal Phase 3 clinical trial of Tonmya for the management of fibromyalgia. In the study, Tonmya met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia. Statistically significant and clinically meaningful results were also seen in all six key secondary endpoints related to improving sleep quality, reducing fatigue and improving overall fibromyalgia symptoms and function. RELIEF, the first statistically significant Phase 3 trial of Tonmya in fibromyalgia, was completed in December 2020. It met its pre-specified primary endpoint of daily pain reduction compared to placebo (p=0.010) and showed activity in key secondary endpoints. In both pivotal studies, the most common treatment-emergent adverse event was tongue or mouth numbness at the administration site, which was temporally related to dosing, self-limited, never rated as severe, and rarely led to study discontinuation (one participant in each study).

 

Tonix Pharmaceuticals Holding Corp.**

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

 

*Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

 

**Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

 

1U.S. National Academies of Sciences, Engineering, and Medicine. 2024. A Long COVID Definition: A chronic, systemic disease state with profound consequences. Washington, DC: The National Academies Press. https://doi.org/10.17226/27768. http://www.nationalacademies.org/long-covid-definition.

 

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

 

This press release and further information about Tonix can be found at www.tonixpharma.com.

 

 

 

 

 

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

 

Peter Vozzo

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

 

Media Contact

Katie Dodge

LaVoieHealthScience

kdodge@lavoiehealthscience.com

(978) 360-3151

 

 

 EX-101.SCH 3 tnxp-20240708.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20240708_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20240708_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 08, 2024
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-20240708.xsd tnxp-20240708_lab.xml tnxp-20240708_pre.xml tnxp-8k_070824.htm http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tnxp-8k_070824.htm": { "nsprefix": "tnxp", "nsuri": "http://tonixpharma.com/20240708", "dts": { "schema": { "local": [ "tnxp-20240708.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "tnxp-20240708_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20240708_pre.xml" ] }, "inline": { "local": [ "tnxp-8k_070824.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://tonixpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_070824.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_070824.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001839882-24-021193-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839882-24-021193-xbrl.zip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end XML 16 tnxp-8k_070824_htm.xml IDEA: XBRL DOCUMENT 0001430306 2024-07-08 2024-07-08 iso4217:USD shares iso4217:USD shares false 0001430306 8-K 2024-07-08 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false